Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
- EligibilityCriteria: Inclusion Criteria:  request for cryopreserved ovarian tissue transplantation; premature ovarian failure or irregular mentrual cycles; negative test for HIV, HBV, HCV, Treponema pallidum; negative PAP test; oncological authorization; absence of neoplastic contamination in the cryopreserved ovarian tissue; Informed consent  Exclusion Criteria:  neoplastic contamination in cryopreserved ovarian tissue; history of endometriosis; endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2); body mass index (BMI) >30 kg/m2; circulating platelet level < 150,000 / mml; bacterial infection; ongoing use of anticoagulants; bleeding diathesis. - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult